Clinical trials showed Xialla to be effective in treating moderate to severe ED when used alone and in combination with drug or injection therapy.
Xialla’s effectiveness was demonstrated in two peer-reviewed clinical trials. Both were featured in the Journal of Sexual Medicine, the world’s premier, authoritative publication in the field of sexual function and dysfunction.
In the first study, Xialla—referred to as a “silicone loop occlusive device”—offered significant erectile function and sexual function benefit to 66% of patients. The second study presented similar findings, with 14 out of 21 post-radical prostatectomy patients experiencing significant benefits. The researchers concluded that Xialla offers “unique properties of fixation and force vector application” in comparison to other penis rings or occlusion devices. Feedback from sexual partners also indicated that Xialla is less obtrusive and more comfortable than other devices.
Littlemore, A., Laing, L., & Bella, A. (2017). 106 Salvage of Post-Prostatectomy Injection Therapy (With and Without Venoseal for Cvod) Treatment Failures by Injection Therapy Coupled With Novel Silicone Loop Occlusion Device. The Journal of Sexual Medicine, 14(1). doi:10.1016/j.jsxm.2016.11.059
Littlemore, A., Laing, L., & Bella, A. (2017). 109 Evaluation of a FDA and Health Canada Compliant Novel Medical Device for Improving Erectile Function Across Erectile Dysfunction Etiologies. The Journal of Sexual Medicine, 14(1). doi:10.1016/j.jsxm.2016.11.062
The clinical trials were conducted by Dr. Anthony Bella and his colleagues. Dr. Bella is one of the world’s foremost urologists. He has written over 100 peer-reviewed publications, chaired the Canadian Urological Association Guidelines, and has written extensively on both clinical care and research topics. Dr. Bella has widely consulted for the pharmaceutical industry, and has held advisory positions for Eli Lilly, Pfizer, Bayer, Abbott, and Endo Pharmaceuticals / American Medical Systems.